-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65

Benzinga·06/25/2026 14:19:35
Listen to the news
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.